19 May 2013
Keywords: positive, data, glivec, early, gist, study, swiss
Article | 23 April 2007
Swiss drug major Novartis says that the interim analysis of data from a study of its anticancer agent Glivec (imatinib) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 April 2007
17 May 2013
© 2013 thepharmaletter.com